Michael Martin Richter

Michael Martin Richter

Auto-generated profile, based on publicly available information

Michael Martin Richter

Department of Clinical Biochemistry, Copenhagen University Hospital – Bispebjerg and Frederiksberg 1

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 October 2024 in Trends in Endocrinology & Metabolism
Verified
Journal Article
Closed access
CSCasper M. Sigvardsen
Casper M. Sigvardsen
MRMichael M. Richter
Michael M. Richter
SESarah Engelbeen
Sarah Engelbeen
MKMaximilian Kleinert
Maximilian Kleinert
ERErik A. Richter
Erik A. Richter

21 July 2022 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Open access
NANicolai Wewer Albrechtsen
Nicolai Wewer Albrechtsen
AMAndreas Møller
Andreas Møller
CMChristoffer Martinussen
Christoffer Martinussen
LGLise L. Gluud
Lise L. Gluud
ERElias B. Rashu
Elias B. Rashu
KBKirstine Nyvold Bojsen-Møller
Kirstine Nyvold Bojsen-Møller
Aims: Sacubitril/valsartan is a neprilysin‐inhibitor/angiotensin II receptor blocker used for the treatment of heart failure. Recently, a post‐hoc analysis of a 3‐year randomized controlled trial showed improved glycaemic control with sacubitril/valsartan in patients with heart failure and type 2 diabetes. We previously reported that sacubitril/valsartan combined with a dipeptidyl peptidase‐4 inhibitor increases active glucagon‐like peptide‐1 (GLP‐1) in healthy individuals. We now hypothesized that administration of sacubitril/valsartan with or without a dipeptidyl peptidase‐4 inhibitor would lower postprandial glucose concentrations (primary outcome) in patients with type 2 diabetes via increased active GLP‐1. Methods: We performed a crossover trial in 12 patients with obesity and type 2 diabetes. A mixed meal was ingested following five respective interventions: (a) a single dose of sacubitril/valsartan; (b) sitagliptin; (c) sacubitril/valsartan + sitagliptin; (d) control (no treatment); and (e) valsartan alone. Glucose, gut and pancreatic hormone responses were measured. Results: Postprandial plasma glucose increased by 57% (incremental area under the curve 0‐240 min) ( p = .0003) and increased peak plasma glucose by 1.7 mM (95% CI: 0.6‐2.9) ( p = .003) after sacubitril/valsartan compared with control, whereas postprandial glucose levels did not change significantly after sacubitril/valsartan + sitagliptin. Glucagon, GLP‐1 and C‐peptide concentrations increased after sacubitril/valsartan, but insulin and glucose‐dependent insulinotropic polypeptide did not change. Conclusions: The glucose‐lowering effects of long‐term sacubitril/valsartan treatment reported in patients with heart failure and type 2 diabetes may not depend on changes in entero‐pancreatic hormones. Neprilysin inhibition results in hyperglucagonaemia and this may explain the worsen glucose tolerance observed in this study. ClinicalTrials.gov (NCT03893526).

24 January 2024 in Journal of the Endocrine Society
Verified
Journal Article
Open access
PDF file
MRMichael M Richter
Michael M Richter
MTMads N Thomsen
Mads N Thomsen
MSMads J Skytte
Mads J Skytte
SKSasha Kjeldsen
Sasha Kjeldsen
ASAmirsalar Samkani
Amirsalar Samkani
NANicolai Wewer Albrechtsen
Nicolai Wewer Albrechtsen
Context Fibroblast growth factor 21 (FGF21) and growth differentiation factor 15 (GDF15) are increased in type 2 diabetes and are potential regulators of metabolism. The effect of changes in caloric intake and macronutrient composition on their circulating levels in patients with type 2 diabetes are unknown. Objective To explore the effects of a carbohydrate-reduced high-protein diet with and without a clinically significant weight loss on circulating levels of FGF21 and GDF15 in patients with type 2 diabetes. Methods We measured circulating FGF21 and GDF15 in patients with type 2 diabetes who completed 2 previously published diet interventions. Study 1 randomized 28 subjects to an isocaloric diet in a 6 + 6-week crossover trial consisting of, in random order, a carbohydrate-reduced high-protein (CRHP) or a conventional diabetes (CD) diet. Study 2 randomized 72 subjects to a 6-week hypocaloric diet aiming at a ∼6% weight loss induced by either a CRHP or a CD diet. Fasting plasma FGF21 and GDF15 were measured before and after the interventions in a subset of samples (n = 24 in study 1, n = 66 in study 2). Results Plasma levels of FGF21 were reduced by 54% in the isocaloric study (P < .05) and 18% in the hypocaloric study (P < .05) in CRHP-treated individuals only. Circulating GDF15 levels increased by 18% (P < .05) following weight loss in combination with a CRHP diet but only in those treated with metformin. Conclusion The CRHP diet significantly reduced FGF21 in people with type 2 diabetes independent of weight loss, supporting the role of FGF21 as a “nutrient sensor.” Combining metformin treatment with carbohydrate restriction and weight loss may provide additional metabolic improvements due to the rise in circulating GDF15.

1 October 2024 in American Journal of Physiology-Gastrointestinal and Liver Physiology
Verified
Journal Article
Closed access
SKSasha Kjeldsen
Sasha Kjeldsen
MWMikkel P. Werge
Mikkel P. Werge
JGJosephine Grandt
Josephine Grandt
MRMichael M. Richter
Michael M. Richter
MTMira Thing
Mira Thing
NANicolai Wewer Albrechtsen
Nicolai Wewer Albrechtsen
Individuals with metabolic dysfunction-associated steatotic liver disease (MASLD) present with increased plasma levels of glucagon (hyperglucagonemia), irrespective of body mass index (BMI) and type 2 diabetes. Therefore, MASLD and the resultant hyperglucagonemia may act as a diabetogenic risk factor. Notably, hepatic steatosis was a significant contributor to the hyperglucagonemia in MASLD, potentially unveiling a pathway for the hyperglucagonemia in some patients with type 2 diabetes.

2 July 2021 in Journal of the Endocrine Society
Verified
Journal Article
Open access
PDF file
MRMichael M Richter
Michael M Richter
PPPeter Plomgaard
Peter Plomgaard
Context Fibroblast growth factor 21 (FGF21), follistatin, angiopoietin-like 4 (ANGPTL4), and growth differential factor 15 (GDF15) are regulated by energy metabolism. Recent findings in humans demonstrate that fructose ingestion increases circulating FGF21, with increased response in conditions of insulin resistance. Objective This study examines the acute effect of fructose and somatostatin on circulating FGF21, follistatin, ANGPTL4, and GDF15 in humans. Methods Plasma FGF21, follistatin, ANGPTL4, and GDF15 concentrations were measured in response to oral ingestion of 75 g of fructose in 10 young healthy males with and without a 15-minute infusion of somatostatin to block insulin secretion. A control infusion of somatostatin was also performed in the same subjects. Results Following fructose ingestion, plasma FGF21 peaked at 3.7-fold higher than basal concentration (P < 0.05), and it increased 4.9-fold compared with basal concentration (P < 0.05) when somatostatin was infused. Plasma follistatin increased 1.8-fold after fructose ingestion (P < 0.05), but this increase was blunted by concomitant somatostatin infusion. For plasma ANGPTL4 and GDF15, no increases were obtained following fructose ingestion. Infusion of somatostatin alone slightly increased plasma FGF21 and follistatin. Conclusion Here we show that in humans (1) the fructose-induced increase in plasma FGF21 was enhanced when somatostatin was infused, suggesting an inhibitory role of insulin on the fructose-induced FGF21 increase; (2) fructose ingestion also increased plasma follistatin, but somatostatin infusion blunted the increase; and (3) fructose ingestion had no stimulating effect on ANGPTL4 and GDF15 levels, demonstrating differences in the hepatokine response to fructose ingestion.

1 November 2025 in American Journal of Physiology-Endocrinology and Metabolism
Verified
Journal Article
Closed access
JRJosephine Reiche
Josephine Reiche
AJAlexander Jakobsen
Alexander Jakobsen
SKSasha Kjeldsen
Sasha Kjeldsen
CRChristine Rasmussen
Christine Rasmussen
LGLise Lotte Gluud
Lise Lotte Gluud
NANicolai Wewer Albrechtsen
Nicolai Wewer Albrechtsen
Here, we investigate the molecular cause for hepatic glucagon resistance in MASLD. We demonstrate that cAMP responses to glucagon are preserved in both humans and mice with liver steatosis, suggesting that the defect lies downstream of cAMP production. These findings redefine the understanding of glucagon resistance and point toward alternative mechanisms beyond second messenger activation.